{"filings":[{"id":863437,"accession_number":"0001193125-26-257760","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-06-04T21:19:05+00:00","items":["5.07"],"status":"ready","headline":"Tango Therapeutics annual meeting elects two Class II directors, ratifies auditor, approves NEO compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Peters elected with 98,188,796 for; 17,623,596 withheld; Rothenberg with 92,476,172 for; 23,336,220 withheld.","Ratification of PricewaterhouseCoopers as 2026 auditor: 131,097,992 for, 73,823 against, 26,266 abstain.","Advisory vote on named executive officer compensation: 113,915,877 for, 1,855,838 against, 40,677 abstain.","Director Kanishka Pothula resigned effective May 13, 2026 prior to meeting; not a disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68483,"accession_number":"0001193125-26-221677","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-05-13T20:16:36+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q1 net loss $45.5M; cash $379.8M; board resignations; vopimetostat combo data due 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $45.5M ($0.32/sh) vs $39.9M ($0.36/sh) YoY; R&D $33.5M, G&A $15.2M.","Cash $379.8M as of March 31, 2026; runway into 2028.","Directors Alexis Borisy and Kanishka Pothula resigned May 13; Sung Lee takes Lead Independent Director and Compensation Chair.","Initial phase 1/2 data for vopimetostat + RAS(ON) inhibitors expected in 2026; registrational path being reviewed.","New leadership appointments: Matthew Gall as CFO, Yen-Ching Chua as CDOO, Janice Kapty as SVP Corp Strategy (April 2026)."],"consensus_eps_estimate":-0.3196,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95758,"accession_number":"0001193125-26-213491","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tango Therapeutics CFO Daniella Beckman Separates; Severance Includes 12-Month Pay, Equity Acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Daniella Beckman ceased serving as principal financial officer effective April 15, 2026.","Separation agreement provides 12 months severance at current base salary paid over 12 months.","Company accelerates vesting of equity awards that would have vested in 24 months following May 1, 2026.","Vested stock options exercise period extended through August 31, 2026.","Beckman executed a general release in favor of the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95757,"accession_number":"0001193125-26-156127","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tango Therapeutics appoints new CFO, additional execs to accelerate vopimetostat development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniella Beckman departs as CFO effective April 15; Matthew Gall named successor.","Matthew Gall receives $540K base salary, 40% target bonus, 240K option shares, 40K RSUs.","Jessica Newcomb appointed principal accounting officer; Yen-Ching Chua named Chief Development Operations Officer.","Janice Kapty named SVP Corporate Strategy and Project Leadership; company focuses on vopimetostat for pancreatic cancer.","Tango plans to present key clinical data in 2026, including combination trial with Revolution Medicines' RAS(ON) inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109054,"accession_number":"0001193125-26-092535","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics reports Q4 net loss $38.7M, cash $343M; vopimetostat pivotal study on track for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.7M for Q4 2025 ($0.29/share) vs $30.8M for Q4 2024; FY2025 net loss $101.6M vs $130.3M.","Cash, equivalents and marketable securities $343.1M as of Dec 31, 2025; runway into 2028.","Collaboration revenue $62.4M for FY2025, including full recognition of remaining Gilead deferred revenue after collaboration truncation.","Vopimetostat pivotal study in 2L MTAP-del pancreatic cancer to start in 2026; initial phase 1/2 combo data with RAS(ON) inhibitors expected in 2026.","Signed clinical supply agreement with Erasca for vopimetostat + pan-RAS molecular glue ERAS-0015; CEO succeeded by Malte Peters in January 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109053,"accession_number":"0001193125-26-007086","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Tango Therapeutics appoints Malte Peters CEO as founder Barbara Weber becomes Executive Chair; cash $343M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barbara Weber, M.D. retires as President and CEO effective Jan 8, 2026; becomes Executive Chair through 2026.","Malte Peters, M.D., board member since 2018, named President and CEO; granted 1.65M options and 350K RSUs.","Cash, cash equivalents and marketable securities totaled $343M as of Dec 31, 2025 (unaudited).","2026 milestones reiterated: vopimetostat combos data, lung cancer update, pancreatic pivotal start, TNG456 data.","Alexis Borisy transitions from Board Chair to Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109052,"accession_number":"0001193125-26-001495","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tango Therapeutics appoints Sung H. Lee to Board; grants option for 60k shares at $8.93","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 8; Lee appointed as Class I director, term until 2028 annual meeting.","Lee to receive stock option for 60,000 shares at $8.93, vesting monthly over 3 years.","Lee to receive RSU for 10,000 shares vesting annually over 3 years; $40k annual retainer.","Lee is EVP & CFO at Cytokinetics, previously CFO at Vir, MorphoSys, Sangamo; 20+ yrs finance experience.","CEO says Lee's expertise will support lead program vopimetostat in registrational studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125521,"accession_number":"0001193125-25-290679","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Tango Therapeutics enters $100M ATM offering with Leerink, terminates Jefferies ATM program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $100M at-the-market common stock sales agreement with Leerink Partners as agent, dated Nov 21, 2025.","Agent commission of up to 3.0% of gross sales price per share sold under the agreement.","Prior $100M Jefferies ATM program terminated effective Nov 21, 2025, with no penalties.","Shares to be sold via at-the-market or negotiated transactions at company's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125520,"accession_number":"0001193125-25-263684","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q3 2025 net income $15.9M; vopimetostat mPFS 7.2 mo in pancreatic; cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $15.9M ($0.14 basic EPS) vs net loss $29.2M in Q3 2024; nine-month net loss $62.8M.","Collaboration revenue $53.8M (Q3 2024: $11.6M) as Gilead collaboration truncated; all deferred revenue recognized.","Vopimetostat in 2L MTAP-del pancreatic cancer showed median PFS 7.2 months; 49% ORR and mPFS 9.1 mo in histology-selective cohort.","October 2025 financing raised $225M gross ($212M net); cash, equivalents and marketables $152.8M as of Sept 30, extending runway into 2028.","TNG456 granted Orphan Drug Designation for malignant glioma; pivotal pancreatic study for vopimetostat anticipated to start 2026."],"consensus_eps_estimate":-0.0538,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":62384000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125519,"accession_number":"0001193125-25-249302","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Tango Therapeutics raises ~$212M via registered direct offering and PIPE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 21.0M shares and 3.2M pre-funded warrants at $8.66; net proceeds ~$197M.","Separate PIPE of 1.7M shares at $8.66 for ~$15M total gross proceeds.","Proceeds to advance pipeline and general corporate purposes; cash runway extended into 2028.","Closings expected October 24, 2025; customary conditions apply.","Officers and directors to enter 60-day lock-up agreements per PIPE terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125518,"accession_number":"0001193125-25-247658","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Tango Therapeutics discloses $152.8M cash; provides vopimetostat clinical update","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Estimated cash, cash equivalents, and marketable securities of $152.8M as of Sept 30, 2025 (preliminary, unaudited).","Clinical slide presentation on ongoing Phase 1/2 trial of vopimetostat (TNG462) made available on Oct 23, 2025.","Cash estimate subject to completion of financial closing procedures and may change materially; auditor has not reviewed.","No full financial results or specific clinical data included in the disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142255,"accession_number":"0001193125-25-187680","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Douglas Barry resigns as Chief Legal Officer and Corporate Secretary of Tango Therapeutics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Barry resigned as Chief Legal and Compliance Officer and Corporate Secretary effective September 12, 2025.","No replacement named; Barry departing to pursue another opportunity.","Resignation covers both officer and corporate secretary roles simultaneously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142254,"accession_number":"0000950170-25-102387","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q2 net loss $38.9M ($0.35/sh); Gilead collab truncated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.9M ($0.35 per share) vs $25.6M ($0.24) in Q2 2024; revenue fell to $3.2M.","Cash $180.8M; expects to fund operations into Q1 2027.","Gilead collaboration research term trimmed from 7 to 5 yrs; $53.8M deferred revenue to be recognized in Q3 2025.","First patients dosed in TNG462 combo with Revolution Medicines RAS(ON) inhibitors and TNG456 Phase 1/2.","TNG462 monotherapy data expected 2H 2025; TNG260 clinical data also expected 2H 2025."],"consensus_eps_estimate":-0.3548,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":8573000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160265,"accession_number":"0001193125-25-137032","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tango Therapeutics shareholders approve doubling authorized shares to 400M, elect new director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common stock from 200M to 400M shares (85.8M for, 11M against).","Lesley Ann Calhoun elected as Class I director with 73.1M votes for, 10.5M withheld.","Ratification of PricewaterhouseCoopers as auditor for FY2025 passed with 96.7M for.","Non-binding say-on-pay passed; annual advisory vote frequency approved (73M votes for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160264,"accession_number":"0000950170-25-068546","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q1 net loss $39.9M; cash runway extended to Q1 2027; TNG462 data update 2H2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.9M ($0.36/share) for Q1 2025 vs $37.9M ($0.35/share) in Q1 2024.","Cash of $216.7M; runway extended into Q1 2027 via reduction in preclinical spend and headcount.","TNG462 Phase 1/2 monotherapy data update expected 2H 2025; registrational study in pancreatic cancer planned for 2026.","Combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors daraxonrasib and zoldonrasib to begin enrollment Q2 2025.","TNG456 Phase 1/2 trial for glioblastoma enrollment expected Q2 2025; TNG260 clinical data update expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":5392000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178561,"accession_number":"0000950170-25-028345","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics reports Q4 2024 net loss of $37.7M; cash runway into 3Q 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.7M for Q4 2024 ($0.35 per share) vs $30.8M loss in Q4 2023; full year net loss $130.3M ($1.19 per share).","Cash and marketable securities $257.9M as of Dec 31, 2024; expected to fund operations into 3Q 2026.","TNG462 granted FDA Orphan Drug Designation for pancreatic cancer; Phase 1/2 data update expected in 2025.","IND for TNG456 cleared; Phase 1/2 enrollment expected 1H 2025; clinical collaboration with Lilly for abemaciclib combination.","TNG260 proof-of-mechanism established; dose expansion ongoing in lung cancer; clinical update expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":42069000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178560,"accession_number":"0001193125-25-004977","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tango Therapeutics discloses $257.9M cash as of Dec 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities totaled $257.9M (unaudited).","Company updated its corporate presentation for use with investors and analysts.","No other financial results or guidance were provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195228,"accession_number":"0000950170-24-121810","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Tango reports Q3 loss $29.2M; TNG462 shows durable activity; PRMT5 program advanced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TNG462 demonstrated clinical activity across multiple tumor types; 43% ORR in cholangiocarcinoma (n=7); median time on treatment 24 weeks and increasing.","Multiple TNG462 combos planned 1H 2025 with RAS(ON) inhibitors (Revolution Medicines), osimertinib, and pembrolizumab.","TNG908 enrollment stopped due to insufficient CNS exposure in glioblastoma; next-gen brain-penetrant TNG456 enters phase 1/2 1H 2025.","Cash $293M as of Sept 30, 2024; cash runway into 3Q 2026; Q3 net loss $29.2M ($0.27/shr) vs $22.3M ($0.23/shr) year ago.","Maeve Waldron-Lynch, M.D. joins as SVP Head of Clinical Development, bringing late-stage oncology regulatory experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":37952000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211482,"accession_number":"0000950170-24-092270","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q2 2024 net loss $25.6M; cash $322M, runway to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.6M ($0.24/share) vs $20.7M loss ($0.23/share) in Q2 2023.","Collaboration revenue $7.8M, down from $9.6M YoY; license revenue $12.1M (incl. $12M Gilead fee).","R&D expenses $38.7M, up from $28.7M YoY due to clinical program advancement.","Cash, equivalents and marketable securities $322.1M; expected to fund operations into 2027.","PRMT5 program (TNG908/TNG462) dose expansion ongoing; comprehensive data update expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":26346000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230143,"accession_number":"0001193125-24-156048","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tango Therapeutics stockholders approve officer liability limit and elect directors at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to Second Amended and Restated Certificate of Incorporation to limit officer liability under Delaware law (89.9M for, 5.5M against).","Elected Alexis Borisy, John Ketchum, and Barbara Weber as Class III directors each with >90M votes for.","Ratified PricewaterhouseCoopers as independent auditor for FY2024 (100.7M for, 2K against).","Quorum of 94.35% (100.7M shares) present at virtual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230142,"accession_number":"0001193125-24-145434","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tango Therapeutics discontinues TNG348 program due to liver toxicity in phase 1/2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2 trial of TNG348, a USP1 inhibitor, terminated because of Grade 3/4 liver function abnormalities in patients on study >8 weeks.","No patient had received TNG348 in combination with olaparib; single-agent toxicity drove decision.","Cash runway extended into 2027; PRMT5 (TNG908/TNG462) and CoREST programs remain on track with clinical update expected H2 2024.","CEO Barbara Weber cited patient safety as priority; stock may react to loss of pipeline candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230141,"accession_number":"0000950170-24-055062","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.","Cash, equivalents and marketable securities of $343.6M as of March 31, 2024.","R&D expense rose to $38.1M from $28.0M due to clinical program advancement.","Dose expansion initiated for TNG908 (PRMT5 inhibitor) in MTAP-deleted tumors.","PRMT5 clinical data update expected in 2H 2024; TNG462 expansion expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":6471000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248576,"accession_number":"0000950170-24-032513","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q4 2023 net loss $30.8M; cash $336.9M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $30.8M ($0.32/sh); full year net loss $101.7M ($1.08/sh).","Cash $336.9M at Dec 31, 2023; plus $41.7M from Jan 2024 ATM; runway into late 2026.","Four phase 1/2 trials ongoing; TNG908 clinical data expected 2024; first patient dosed for TNG348.","FDA Orphan Drug Designation granted for TNG462 for soft tissue sarcomas.","Appointed Chief Regulatory Officer, Chief Development Operations Officer, Chief Legal Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}